Dystrophin Market Overview, Industry Top Manufactures, Size, Growth 2019-2026

High disease prevalence across the globe coupled with ongoing research & development is expected to stimulate market growth

Market Size – USD 597.3 million in 2018, Market Growth - CAGR of 47.0%, Market Trends – Product launches and ongoing clinical trials 

According to the current analysis of Reports and Data, the global Dystrophin Market was valued at 0.60 billion in 2018 and is expected to reach USD 13.02 billion by year 2026, at a CAGR of 47% percent. The growth of the dystrophin market is more in countries such as U.S, Austria, Czech Republic, Denmark, Germany, Hungary, Israel, Italy, Norway, Portugal, Slovakia, South Korea, and the United Kingdom; where key muscular dystrophy drugs are available in the market.

The market is characterized by the entry of a large number of players that includes emerging companies, as well as healthcare giants. The primary factor, for the focus of market players, is the unaddressed demand for treatment of muscular dystrophy diseases for a long time. There are over 35 companies engaged in clinical trials for the launch of novel therapeutics for the treatment of DMD. However, owing to stringent regulation across the globe for drug approval, very few drug candidates have received approval by medicine regulatory bodies such as the US Food and Drug Administration (FDA), and European Commission.

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/press-release/global-dystrophin-market 
Further key findings from the report suggest

• Exon Skipping accounted for 45.3% of the overall industry in 2017 and will witness high growth owing to anticipated adoption across the globe after regulatory approval in Europe and other parts of the world. However, low awareness about therapeutics in developing nations is expected to hamper its growth over the forecast period.
• Asia Pacific market was valued at USD 14.1 million in 2017 and is expected to reflect significant growth during the forecast period owing it to anticipated drug launches in the region. Favorable scenario for research and development funds and the presence of various emerging players in the region is likely to promote market growth over the forecast period. As of 2017, there is a lack of well-established effective muscular dystrophy therapy in the region, which is a significant factor for the low market share of the region.
• Key participants include PTC Therapeutics, Sarepta Therapeutics, BioMarin Pharmaceutical Inc, Wave Life Sciences, Bristol-Myers Squibb and Catabasis Pharmaceuticals among others. PTC Therapeutics has a market presence through its muscular dystrophy drugs under the brand name, Emflaza, and Translarna. As of 2017, PTC Therapeutics dominated the market followed by Sarepta Therapeutics.

For this report, Reports and Data have segmented the global dystrophin market on the basis of product, approach, and region:

• Product Outlook (Revenue, USD Million, 2016 - 2026)
  • Exondys51
  • Translarna
  • Emflaza
  • Others
• Approach Outlook (Revenue, USD Million, 2016 - 2026)
• Exon Skipping
• Anti-Inflammatory Therapy
• Stop Codon Read-Through
• Others Approaches

Request For Free PDF Sample Of This Research Report At: https://www.reportsanddata.com/sample-enquiry-form/1063 

• Regional Outlook (Revenue, USD Million, 2016 - 2025)
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia-Pacific
  • Rest of the World